$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414047210 Filed on August 06, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$860.0K	$830.0K
YoY Change		84.44%
% of Gross Profit
Research & Development	$530.0K	$320.3K
YoY Change		632.22%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$1.390M	$1.146M	$960.0K
YoY Change	44.79%	131.67%	540.0%
Operating Profit		-$1.146M
YoY Change		131.67%
Interest Expense	$2.020M	$27.76K
YoY Change		41.68%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change
Pretax Income	$640.0K	$410.0K	-$960.0K
YoY Change	-166.67%	-180.39%	405.26%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%	0.0%
Net Earnings	$640.0K	$410.8K	-$960.0K
YoY Change	-166.67%	-179.86%	405.26%
Net Earnings / Revenue
Basic Earnings Per Share		$0.01
Diluted Earnings Per Share	$8.868K	$0.01	-$44.92K
COMMON SHARES
Basic Shares Outstanding	72.08M shares	71.95M shares	59.15M shares
Diluted Shares Outstanding		72.08M shares

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$830.0K	$1.800M	$560.0K
YoY Change	48.21%	275.0%	2700.0%
Cash & Equivalents	$833.5K	$1.803M	$557.3K
Short-Term Investments
Other Short-Term Assets	$40.00K	$30.00K	$20.00K
YoY Change	100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$877.0K	$1.835M	$1.577M
YoY Change	-44.39%	284.24%	7612.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$322.00
YoY Change	-100.0%	-100.0%	-64.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$10.06K
YoY Change	-100.0%
Total Long-Term Assets	$0.00	$0.00	$10.38K
YoY Change	-100.0%	-100.0%	1043.61%
TOTAL ASSETS
Total Short-Term Assets	$877.0K	$1.835M	$1.577M
Total Long-Term Assets	$0.00	$0.00	$10.38K
Total Assets	$877.0K	$1.835M	$1.587M
YoY Change	-44.75%	284.2%	7333.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$175.8K	$166.0K	$314.8K
YoY Change	-44.14%	-46.02%	21.8%
Accrued Expenses	$270.0K	$220.0K	$140.0K
YoY Change	92.86%		-60.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$2.724M	$3.460M	$455.6K
YoY Change	497.81%	725.28%	-82.15%
LONG-TERM LIABILITIES
Long-Term Debt	$960.0K	$950.0K	$940.0K
YoY Change	2.13%		291.67%
Other Long-Term Liabilities	$4.090M	$5.320M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$5.046M	$6.272M	$944.7K
YoY Change	434.11%		291.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.724M	$3.460M	$455.6K
Total Long-Term Liabilities	$5.046M	$6.272M	$944.7K
Total Liabilities	$7.769M	$9.732M	$1.400M
YoY Change	454.83%	2221.22%	-49.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.77M		-$4.632M
YoY Change	175.8%
Common Stock	$5.882M	$72.00K	$60.15K
YoY Change	9680.12%	22.77%	965.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.892M	-$7.897M	$187.0K
YoY Change
Total Liabilities & Shareholders Equity	$877.0K	$1.835M	$1.587M
YoY Change	-44.75%	284.2%	7333.07%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q3
OPERATING ACTIVITIES
Net Income	$640.0K	$410.8K	-$960.0K
YoY Change	-166.67%	-179.86%	405.26%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$970.0K	-$740.0K	-$660.0K
YoY Change	46.97%	48.0%	560.0%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-100.0K	750.0K
YoY Change	-100.0%	-110.31%	650.0%
NET CHANGE
Cash From Operating Activities	-970.0K	-740.0K	-660.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	0.000	-100.0K	750.0K
Net Change In Cash	-970.0K	-840.0K	90.00K
YoY Change	-1177.78%	-278.72%	-309237645312000600.0%
FREE CASH FLOW
Cash From Operating Activities	-$970.0K	-$740.0K	-$660.0K
Capital Expenditures		$0.00
Free Cash Flow		-$740.0K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	62211	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	75270	USD
CY2014Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	1584818	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Net Income Loss NetIncomeLoss	-13409708	USD
CY2013Q2	arth	Percentage Of Outstanding Number Of Shares PercentageOfOutstandingNumberOfShares	0.04	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.86	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.86	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.15	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.15	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0091	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0091	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0277	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0277	pure
CY2014Q2	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	245245	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	748600	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y22D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4869212	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	231250	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7637962	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2546470	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7637962	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.36
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.36
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.36
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.36
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm	P0Y
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y5M26D
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P5Y29D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y5M26D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29600	USD
	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	6100	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	29600	USD
CY2013Q3	us-gaap	Notes Payable NotesPayable	944707	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32206	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	55293	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1802524	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	557319	USD
CY2014Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	0	USD
CY2013Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	1000000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19629	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	1834730	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	1576948	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	322	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10062	USD
CY2014Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	0	USD
CY2013Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	10384	USD
CY2014Q2	us-gaap	Assets Assets	1834730	USD
CY2013Q3	us-gaap	Assets Assets	1587332	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	166011	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	314769	USD
CY2014Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	216110	USD
CY2013Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	140840	USD
CY2014Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3078000	USD
CY2013Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3460121	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	455609	USD
CY2014Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	953002	USD
CY2013Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	944707	USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	75000	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	0	USD
CY2014Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5244000	USD
CY2013Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2014Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6272002	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	944707	USD
CY2014Q2	us-gaap	Liabilities Liabilities	9732123	USD
CY2013Q3	us-gaap	Liabilities Liabilities	1400316	USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	72001	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	60145	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5440314	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4758742	USD
CY2014Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	13409708	USD
CY2013Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	4631871	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	-7897393	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	187016	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1834730	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1587332	USD
CY2014Q2	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	1000000	USD
CY2013Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1880000	USD
CY2012Q3	arth	Matured Convertible Notes MaturedConvertibleNotes	1245000	USD
CY2012Q4	arth	Matured Convertible Notes MaturedConvertibleNotes	50000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	10391693	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2850000	USD
	arth	Fair Value Of Derivative Liabilities In Excess Of Proceeds FairValueOfDerivativeLiabilitiesInExcessOfProceeds	7541693	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	2069693	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72076487	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60145237	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72076487	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60145237	shares
	us-gaap	Revenues Revenues	431461	USD
CY2013Q2	us-gaap	Revenues Revenues	0	USD
CY2014Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5819918	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	451046	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	825951	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	721565	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2271443	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1931341	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43750	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	320345	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62356	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	951101	USD
	us-gaap	Operating Expenses OperatingExpenses	7751259	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	494796	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	1146296	USD
	us-gaap	Operating Expenses OperatingExpenses	783921	USD
	us-gaap	Operating Expenses OperatingExpenses	3222544	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7319798	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-494796	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1146296	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-783921	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3222544	USD
	us-gaap	Interest Expense InterestExpense	671887	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	19596	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	27763	USD
	us-gaap	Interest Expense InterestExpense	108384	USD
	us-gaap	Interest Expense InterestExpense	83293	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	2069693	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	0	USD
	us-gaap	Other Income OtherIncome	53977	USD
CY2013Q2	us-gaap	Other Income OtherIncome	32	USD
CY2014Q2	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	51	USD
	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6089910	USD
CY2013Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-19564	USD
CY2014Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1557055	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-108333	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5555293	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-514360	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	410759	USD
	us-gaap	Net Income Loss NetIncomeLoss	-892254	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8777837	USD
	us-gaap	Depreciation Depreciation	18693	USD
	us-gaap	Depreciation Depreciation	847	USD
	us-gaap	Depreciation Depreciation	322	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	98252	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2859	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	92500	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1036527	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	748600	USD
	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	83295	USD
	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	0	USD
	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	83295	USD
	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	441253	USD
	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	82147	USD
	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	0	USD
	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	142057	USD
	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	25599	USD
	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	0	USD
	arth	Repayment Of Accrued Interest To Related Parties RepaymentOfAccruedInterestToRelatedParties	-98288	USD
	arth	Repayment Of Accrued Interest To Related Parties RepaymentOfAccruedInterestToRelatedParties	-98288	USD
	arth	Repayment Of Accrued Interest To Related Parties RepaymentOfAccruedInterestToRelatedParties	0	USD
	arth	Non Cash Expense For Issuance Of Warrants NonCashExpenseForIssuanceOfWarrants	5472000	USD
	arth	Non Cash Expense For Issuance Of Warrants NonCashExpenseForIssuanceOfWarrants	0	USD
	arth	Non Cash Expense For Issuance Of Warrants NonCashExpenseForIssuanceOfWarrants	5472000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	77878	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	77625	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	22144	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2187	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2515	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	10062	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	166011	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	49122	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-148758	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	216110	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5788126	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-765570	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2379498	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19053	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19053	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	4624703	USD
	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1250000	USD
	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	2624703	USD
	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	-275200	USD
	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	-275200	USD
	arth	Proceeds From Repayments Of Notes Payable Related Parties ProceedsFromRepaymentsOfNotesPayableRelatedParties	0	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	275200	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	105000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1880000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7609703	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1224800	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3624703	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1802524	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	459230	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1245205	USD
CY2006Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17139	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	476369	USD
	us-gaap	Interest Paid InterestPaid	98288	USD
	us-gaap	Interest Paid InterestPaid	98288	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	1000000	USD
	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	0	USD
	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	0	USD
	arth	Stock Issued During Period Value Exchange Of Debt And Accrued Interest StockIssuedDuringPeriodValueExchangeOfDebtAndAccruedInterest	2470022	USD
	arth	Stock Issued During Period Value Exchange Of Debt And Accrued Interest StockIssuedDuringPeriodValueExchangeOfDebtAndAccruedInterest	0	USD
	arth	Stock Issued During Period Value Exchange Of Debt And Accrued Interest StockIssuedDuringPeriodValueExchangeOfDebtAndAccruedInterest	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Arch Therapeutics, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ARTH
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72076487	shares
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8549322	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71949564	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6613249	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65933378	shares
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2013Q2	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	8549322	shares
CY2014Q2	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	72084748	shares
	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	6613249	shares
	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	65933378	shares
	arth	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	7541693	USD
CY2013Q2	arth	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2014Q2	arth	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
	arth	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
	arth	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	7541693	USD
CY2014Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	2765	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	8294	USD
CY2014Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8322000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2000000	USD
CY2013Q2	arth	Unit Issued Price Per Share UnitIssuedPricePerShare	0.50
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2013Q2	arth	Proceeds From Investors In Contemplation Of Merger ProceedsFromInvestorsInContemplationOfMerger	2000000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3000000	shares

Files In Submission

Name	View Source	Status
0001144204-14-047210-index-headers.html	Edgar Link	pending
0001144204-14-047210-index.html	Edgar Link	pending
0001144204-14-047210.txt	Edgar Link	pending
0001144204-14-047210-xbrl.zip	Edgar Link	pending
arth-20140630.xml	Edgar Link	completed
arth-20140630.xsd	Edgar Link	pending
arth-20140630_cal.xml	Edgar Link	unprocessable
arth-20140630_def.xml	Edgar Link	unprocessable
arth-20140630_lab.xml	Edgar Link	unprocessable
arth-20140630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v385177_10q.htm	Edgar Link	pending
v385177_ex31-1.htm	Edgar Link	pending
v385177_ex31-2.htm	Edgar Link	pending
v385177_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2014 Q3 Form 10-Q Financial Statement

#000114420414047210 Filed on August 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2014 Q3 Form 10-Q Financial Statement

#000114420414047210 Filed on August 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth